Abbvie Inc. vs Incyte Genomics Inc
ABBV vs INCY — side-by-side comparison from reported financials. ABBV leads 3, INCY leads 5 of 8 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Incyte Genomics Inc
INCY · Healthcare
$112.79+0.04%Mixed
| Metric | ABBV | INCY |
|---|---|---|
| Price | $276.43 | $112.79 |
| Market cap | $488B | $22.9B |
| Revenue (TTM) | $64.4B | $5.82B |
| Revenue growth | +1.8% | +14.8% |
| Net margin | 9.8% | 27.7% |
| Free cash flow | $18.2B | $1.98B |
| Net cash (debt) | ($56.2B) | — |
| 1-year price return | +19.8% | +33.1% |
| P/E | 77.4 | 14.2 |
| P/E vs own history (cheap-side %) | 23% | 96% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 30% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 57,000 | 2,844 |
Full résumé-style profiles: ABBV CV · INCY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.